Viral and fungal infection after liver transplantation - Part II

Liver Transplantation

Volumn 12, Issue 1, 2006, Pages 2-11

  Kusne, Shimon ^a,b   Blair, Janis E ^a  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; BLEOMYCIN SULFATE; CASPOFUNGIN; CIDOFOVIR; CORTICOSTEROID; CYTOMEGALOVIRUS ANTIBODY; DOXORUBICIN; ECHINOCANDIN; FAMCICLOVIR; FLUCONAZOLE; FLUCYTOSINE; FOSCARNET; GANCICLOVIR; ITRACONAZOLE; LYMPHOCYTE ANTIBODY; MICAFUNGIN; PLACEBO; RIBAVIRIN; STEROID; TSUKUBAENOLIDE; VALACICLOVIR; VALGANCICLOVIR; VINCRISTINE; VORICONAZOLE; ANTIVIRUS AGENT;

CHEMOPROPHYLAXIS; CLINICAL PRACTICE; CLINICAL TRIAL; CYTOMEGALOVIRUS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG MEGADOSE; DRUG USE; EARLY DIAGNOSIS; ENCEPHALITIS; FEVER; GRAFT RECIPIENT; HUMAN; HUMAN HERPESVIRUS 6; HUMAN HERPESVIRUS 8; KAPOSI SARCOMA; LIVER TRANSPLANTATION; LOW DRUG DOSE; MORBIDITY; MORTALITY; MYCOSIS; NEPHROTOXICITY; OUTCOME ASSESSMENT; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RASH; REVIEW; VIRUS INFECTION; ADULT; AGE DISTRIBUTION; COMPARATIVE STUDY; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HOSPITALIZATION; INCIDENCE; MALE; METHODOLOGY; MIDDLE AGED; POSTOPERATIVE COMPLICATION; PROGNOSIS; RISK ASSESSMENT; SEX RATIO; SURVIVAL;

ADULT; AGE DISTRIBUTION; ANTIFUNGAL AGENTS; ANTIVIRAL AGENTS; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; INCIDENCE; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; MYCOSES; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SEX DISTRIBUTION; SURVIVAL ANALYSIS; VIRUS DISEASES;

EID: 33645100314     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.20667     Document Type: Review

References (84)

1. Fishman JA, Rubin RH. Infection in organ-transplant recipients. N Engl J Med 1998;338:1741-1751.
2. Rubin RH. The direct and indirect effects of infection in liver transplantation: pathogenesis, impact, and clinical management. Curr Clin Top Infect Dis 2002;22:125-154.
3. George MJ, Snydman DR, Werner BG, Griffith J, Falagas ME, Dougherty NN, et al. Boston Center for Liver Transplantation CMVIG-Study Group. Cytogam, MedImmune, Inc. Gaithersburg, Maryland. The independent role of cytomegalovirus as a risk factor for invasive fungal disease in orthotopic liver transplant recipients. Am J Med 1997; 103:106-113.
4. O'Grady JG, Alexander GJ, Sutherland S, Donaldson PT, Harvey F, Portmann B, et al. Cytomegalovirus infection and donor/recipient HLA antigens: interdependent co-factors in pathogenesis of vanishing bile-duct syndrome after liver transplantation. Lancet 1988;2:302-305.
5. Ljungman P, Plotkin SA. Workshop on CMV disease: definitions, clinical severity scores, and new syndromes. Scand J Infect Dis 1995;99:S87-S89.
6. Gaeta A, Nazzari C, Angeletti S, Lazzarini M, Mazzei E, Mancini C. Monitoring for cytomegalovirus infection in organ transplant recipients: analysis of pp65 antigen, DNA and late mRNA in peripheral blood leukocytes. J Med Virol 1997;53:189-195.
7. Gerna G, Revello MG, Percivalle E, Morini F. Comparison of different immunostaining techniques and monoclonal antibodies to the lower matrix phosphoprotein (pp65) for optimal quantitation of human cytomegalovirus antigenemia. J Clin Microbiol 1992;30:1232-1237.
8. Kusne S, Shapiro R, Fung J. Prevention and treatment of cytomegalovirus infection in organ transplant recipients. Transpl Infect Dis 1999;1:187-203.
9. Keating MR. Antiviral agents. Mayo Clin Proc 1992;67: 160-178.
10. Zanetta G, Maurice-Estepa L, Mousson C, Justrabo E, Daudon M, Rifle G, et al. Foscarnet-induced crystalline glomerulonephritis with nephrotic syndrome and acute renal failure after kidney transplantation. Transplantation 1999;67:1376-1378.
11. Limaye AP, Corey L, Koelle DM, Davis CL, Boeckh M. Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. Lancet 2000;356:645-649.
12. Martin M, Manez R, Linden P, Estores D, Torre-Cisneros J, Kusne S, et al. A prospective randomized trial comparing sequential ganciclovir-high dose acyclovir to high dose acyclovir for prevention of cytomegalovirus disease in adult liver transplant recipients. Transplantation 1994; 58:779-785.
13. Gane E, Saliba F, Valdecasas GJ, O'Grady J, Pescovitz MD, Lyman S, et al. The Oral Ganciclovir International Transplantation Study Group: randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. Lancet 1997;350:1729-33. Erratum in: Lancet 1998;351:454.
14. Paya C, Humar A, Dominguez E, Washburn K, Blumberg E, Alexander B, et al. Valganciclovir Solid Organ Transplant Study Group: efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2004;4:611-620.
15. Snydman DR, Werner BG, Dougherty NN, Griffith J, Rubin RH, Dienstag JL, et al. Boston Center for Liver Transplantation CMVIG Study Group: cytomegalovirus immune globulin prophylaxis in liver transplantation: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1993;119:984-991.
16. Rubin RH. Preemptive therapy in immunocompromised hosts. N Engl J Med 1991;324:1057-1059.
17. Kusne S, Grossi P, Irish W, St George K, Rinaldo C, Rakela J, et al. Cytomegalovirus PP65 antigenemia monitoring as a guide for preemptive therapy: a cost effective strategy for prevention of cytomegalovirus disease in adult liver transplant recipients. Transplantation 1999;68:1125-1131.
18. Paya CV, Wilson JA, Espy MJ, Sia IG, DeBernardi MJ, Smith TF, et al. Preemptive use of oral ganciclovir to prevent cytomegalovirus infection in liver transplant patients: a randomized, placebo-controlled trial. J Infect Dis 2002 Apr 1;185:854-860. Epub 2002 Mar 19.
19. Hibberd PL, Tolkoff-Rubin NE, Conti D, Stuart F, Thistlethwaite JR, Neylan JF, et al. Preemptive ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus antibody-positive renal transplant recipients: a randomized controlled trial. Ann Intern Med 1995;123:18-26.
20. Randhawa PS, Markin RS, Starzl TE, Demetris AJ. Epstein-Barr virus-associated syndromes in immunosuppressed liver transplant recipients: clinical profile and recognition on routine allograft biopsy. Am J Surg Pathol 1990;14:538-547.
21. Paya CV, Fung JJ, Nalesnik MA, Kieff E, Green M, Gores G, et al. ASTS/ASTP EBV-PTLD Task Force and The Mayo Clinic Organized International Consensus Development Meeting: Epstein-Barr virus-induced posttransplant lymphoproliferative disorders. Transplantation 1999;68: 1517-1525.
22. Jain A, Nalesnik M, Reyes J, Pokharna R, Mazariegos G, Green M, et al. Posttransplant lymphoproliferative disorders in liver transplantation: a 20-year experience. Ann Surg 2002;236:429-436.
23. Frizzera G, Hanto DW, Gajl-Peczalska KJ, Rosai J, McKenna RW, Sibley RK, et al. Polymorphic diffuse B-cell hyperplasias and lymphomas in renal transplant recipients. Cancer Res 1981;41:4262-4279.
24. Nalesnik MA. Clinicopathologic characteristics of posttransplant lymphoproliferative disorders. Recent Results Cancer Res 2002;159:9-18.
25. Swinnen LJ, Costanzo-Nordin MR, Fisher SG, O'Sullivan EJ, Johnson MR, Heroux AL, et al. Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients. N Engl J Med 1990:323:1723-1728.
26. Walker RC, Marshall WF, Strickler JG, Wiesner RH, Velosa JA, Habermann TM, et al. Pretransplantation assessment of the risk of lymphoproliferative disorder. Clin Infect Dis 1995;20:1346-1353.
27. Manez R, Breinig MK, Linden P, Kusne S, Torre-Cisneros J, Wilson J, et al. Factors associated with the development of post-transplant lymphoproliferative disease (PTLD) in Epstein-Barr virus (EBV)-seronegative adult liver transplant recipients. Transpl Int 1994:7:S235-S237.
28. Green M. Management of Epstein-Barr virus-induced post-transplant lymphoproliferative disease in recipients of solid organ transplantation. Am J Transplant. 2001;1: 103-108.
29. Starzl TE, Nalesnik MA, Porter KA, Ho M, Iwatsuki S, Griffith BP, et al. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet 1984;1:583-587.
30. Fischer A, Blanche S, Le Bidois J, Bordigoni P, Garnier JL, Niaudet P, et al. Anti-B-cell monoclonal antibodies in the treatment of severe B-cell lymphoproliferative syndrome following bone marrow and organ transplantation. N Engl J Med 1991;324:1451-1456.
31. Rooney CM, Smith CA, Ng CY, Loftin SK, Sixbey JW, Gan Y, et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 1998;92:1549-1555.
32. Liu Z, Savoldo B, Huls H, Lopez T, Gee A, Wilson J, et al. Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the prevention and treatment of EBV-associated posttransplant lymphomas: Recent Results. Cancer Res 2002; 159:123-133.
33. Kusne S, Dummer JS, Singh N, Iwatsuki S, Makowka L, Esquivel C, et al. Infections after liver transplantation: an analysis of 101 consecutive cases. Medicine (Baltimore) 1988;67:132-143.
34. Feldman S, Stokes DC. Varicella zoster and herpes simplex virus pneumonias. Semin Respir Infect 1987;2:84-94.
35. Kusne S, Pappo O, Manez R, Pazin G, Carpenter B, Fung JJ, et al. Varicella-zoster virus hepatitis and a suggested management plan for prevention of VZV infection in adult liver transplant recipients. Transplantation 1995;60:619-621.
36. Kusne S, Schwartz M, Breinig MK, Dummer JS, Lee RE, Selby R, et al. Herpes simplex virus hepatitis after solid organ transplantation in adults. J Infect Dis 1991;163: 1001-1007.
37. Cirelli R, Herne K, McCrary M, Lee P, Tyring SK. Famciclovir: review of clinical efficacy and safety. Antiviral Res 1996;29:141-151.
38. Tyring SK, Baker D, Snowden W. Valacyclovir for herpes simplex virus infection: long-term safety and sustained efficacy after 20 years' experience with acyclovir. J Infect Dis 2002;186:S40-S46.
39. Cames B, Rahier J, Burtomboy G, de Ville de Goyet J, Reding R, Lamy M, et al. Acute adenovirus hepatitis in liver transplant recipients. J Pediatr 1992;120:33-37.
40. Koneru B, Jaffe R, Esquivel CO, Kunz R, Todo S, Iwatsuki S, et al. Adenoviral infections in pediatric liver transplant recipients. JAMA 1987;258:489-492.
41. Michaels MG, Green M, Wald ER, Starzl TE. Adenovirus infection in pediatric liver transplant recipients. J Infect Dis 1992;165:170-174.
42. Mendez JC, Dockrell DH, Espy MJ, Smith TF, Wilson JA, Harmsen WS, et al. Human beta-herpesvirus interactions in solid organ transplant recipients. J Infect Dis 2001 Jan 15;183:179-184. Epub 2000 Dec 15.
43. Razonable RR, Rivero A, Brown RA, Hart GD, Espy MJ, van Cruijsen H, et al. Detection of simultaeous beta-herpesvirus infections in clinical syndromes due to defined cytomegalovirus infection. Clin Transplant 2003;17:114-120.
44. Okuno T, Takahashi K, Balachandra K, Shiraki K, Yamanishi K, Takahashi M, et al. Seroepidemiology of human herpesvirus 6 infection in normal children and adults. J Clin Microbiol. 1989;27:651-653.
45. Razonable RR, Paya CV. The impact of human herpesvirus-6 and -7 infection on the outcome of liver transplantation. Liver Transpl 2002;8:651-658.
46. Lautenschlager I, Linnavuori K, Hockerstedt K. Human herpesvirus-6 antigenemia after liver transplantation. Transplantation 2000;69:2561-2566.
47. Singh N, Carrigan DR, Gayowski T, Marino IR. Human herpesvirus-6 infection in liver transplant recipients: documentation of pathogenicity. Transplantation 1997;64:674-678.
48. Singh N, Paterson DL. Encephalitis caused by human herpesvirus-6 in transplant recipients: relevance of a novel neurotropic virus. Transplantation 2000;69:2474-2479.
49. Rogers J, Rohal S, Carrigan DR, Kusne S, Knox KK, Gayowski T, et al. Human herpesvirus-6 in liver transplant recipients: role in pathogenesis of fungal infections, neurologic complications, and outcome. Transplantation 2000;69:2566-2573.
50. Antman K, Chang Y. Kaposi's sarcoma. N Engl J Med 2000;342:1027-1038.
51. Pozo F, Tenorio A, de la Mata M, de Ory F, Torre-Cisneros J. Persistent human herpesvirus 8 viremia before Kaposi's sarcoma development in a liver transplant recipient. Transplantation 2000;70:395-397.
52. Kadry Z, Bronsther O, Van Thiel DH, Randhawa P, Fung JJ, Starzl TE. Kaposi's sarcoma in two primary liver allograft recipients occurring under FK506 immunosuppression. Clin Transplant 1993;7:188-194.
53. Regamey N, Tamm M, Wernli M, Witschi A, Thiel G, Cathomas G, et al. Transmission of human herpesvirus 8 infection from renal-transplant donors to recipients. N Engl J Med 1998;339:1358-1363.
54. Parravicini C, Olsen SJ, Capra M, Poli F, Sirchia G, Gao SJ, et al. Risk of Kaposi's sarcoma-associated herpes virus transmission from donor allografts among Italian posttransplant Kaposi's sarcoma patients. Blood 1997;90: 2826-2829.
55. Jenkins FJ, Hoffman LJ, Liegey-Dougall A. Reactivation of and primary infection with human herpesvirus 8 among solid-organ transplant recipients. J Infect Dis 2002;185: 1238-1243. Epub 2002 Apr 9.
56. Verucchi G, Calza L, Trevisani F, Zambruni A, Tadolini M, Giuliani R, et al. Human herpesvirus-8-related Kaposi's sarcoma after liver transplantation successfully treated with cidofovir and liposomal daunorubicin. Transpl Infect Dis 2005;7:34-37.
57. Ascioglu S, Rex JH, de Pauw B, Bennett JE, Bille J, Crokaert F, et al, Invasive Fungal Infections Cooperative Group of the European Organization for Research and Treatment of Cancer; Mycoses Study Group of the National Institute of Allergy and Infectious Diseases. Defining opportunistic invasive fungal infections in immuno-compromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002;34:7-14. Epub 2001 Nov 26.
58. Tiphine M, Letscher-Bru V, Herbrecht R. Amphotericin B and its new formulations: pharmacologic characteristics, clinical efficacy, and tolerability. Transpl Infect Dis 1999; 1:273-283.
59. Zaas AK, Alexander BD. Echinocandins: role in antifungal therapy, 2005. Expert Opin Pharmacother 2005;6:1657-1668.
60. Linden PK, Coley K, Fontes P, Fung JJ, Kusne S. Invasive aspergillosis in liver transplant recipients: outcome comparison of therapy with amphotericin B lipid complex and a historical cohort treated with conventional amphotericin B. Clin Infect Dis 2003;37:17-25. Epub 2003 Jun 20.
61. Wajszczuk CP, Dummer JS, Ho M, Van Thiel DH, Starzl TE, Iwatsuki S, et al. Fungal infections in liver transplant recipients. Transplantation 1985:40:347-353.
62. Fung JJ. Fungal infection in liver transplantation. Transpl Infect Dis 2002;4:18-23.
63. Collins LA, Samore MH, Roberts MS, Luzzati R, Jenkins RL, Lewis WD, et al. Risk factors for invasive fungal infections complicating orthotopic liver transplantation. J Infect Dis 1994;170:644-652.
64. Singh N, Gayowski T, Wagener MM, Doyle H, Marino IR. Invasive fungal infections in liver transplant recipients receiving tacrolimus as the primary immunosuppressive agent. Clin Infect Dis 1997;24:179-184.
65. Briegel J, Forst H, Spill B, Haas A, Grabein B, Haller M, et al. Risk factors for systemic fungal infections in liver transplant recipients. Eur J Clin Microbiol Infect Dis 1995;14:375-382.
66. Castaldo P, Stratta RJ, Wood RP, Markin RS, Patil KD, Shaefer MS, et al. Clinical spectrum of fungal infections after orthotopic liver transplantation. Arch Surg 1991; 126:149-156.
67. Patel R, Portela D, Badley AD, Harmsen WS, Larson-Keller JJ, Ilstrup DM, et al. Risk factors of invasive Candida and non-Candida fungal infections after liver transplantation. Transplantation 1996;62:926-934.
68. Fortun J, Martin-Davila P, Moreno S, Barcena R, de Vicente E, Honrubia A, et al. Prevention of invasive fungal infections in liver transplant recipients: the role of prophylaxis with lipid formulations of amphotericin B in high-risk patients. J Antimicrob Chemother 2003;52:813-819. Epub 2003 Oct 16.
69. Winston DJ, Pakrasi A, Busuttil RW. Prophylactic fluconazole in liver transplant recipients: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1999:131: 729-737.
70. Sharpe MD, Ghent C, Grant D, Horbay GL, McDougal J, David Colby W. Efficacy and safety of itraconazole prophylaxis for fungal infections after orthotopic liver transplantation: a prospective, randomized, double-blind study. Transplantation 2003;76:977-983.
71. Winston DJ, Busuttil RW. Randomized controlled trial of oral itraconazole solution versus intavenous/oral fluconazole for prevention of fungal infections in liver transplant recipients. Transplantation 2002;74:688-695.
72. Biancofiore G, Bindi ML, Baldassarri R, Romanelli AM, Catalano G, Filipponi F, et al. Antifungal prophylaxis in liver transplant recipients: a randomized placebo-controlled study. Transpl Int 2002;15:341-347. Epub 2002 Jun 20.
73. Singhal S, Ellis RW, Jones SG, Miller SJ, Fisher NC, Hastings JG, et al. Targeted prophylaxis with amphotericin B lipid complex in liver transplantation. Liver Transpl 2000; 6:588-595.
74. Kusne S, Tobin D, Pasculle AW, Van Thiel DH, Ho M, Starzl TE. Candida carriage in the alimentary tract of liver transplant candidates. Transplantation 1994;57:398-402.
75. Fortun J, Lopez-San Roman A, Velasco JJ, Sanchez-Sousa A, de Vicente E, Nuno J, et al. Selection of Candida glabrata strains with reduced susceptibility to azoles in four liver transplant patients with invasive candidiasis. Eur J Clin Microbiol Infect Dis 1997;16:314-318.
76. Husain S, Tollemar J, Dominguez EA, Baumgarten K, Humar A, Paterson DL, et al. Changes in the spectrum and risk factors for invasive candidiasis in liver transplant recipients: prospective, multicenter, case-controlled study. Transplantation 2003;75:2023-2029.
77. Kusne S, Torre-Cisneros J, Manez R, Irish W, Martin M, Fung J, et al. Factors associated with invasive lung aspergillosis and the significance of positive Aspergillus culture after liver transplantation. J Infect Dis 1992;166: 1379-1383.
78. Horvath JA, Dummer S. The use of respiratory-tract cultures in the diagnosis of invasive pulmonary aspergillosis. Am J Med. 1996;100:171-178.
79. Singh N, Arnow PM, Bonham A, Dominguez E, Paterson DL, Pankey GA, et al. Invasive aspergillosis in liver transplant recipients in the 1990s. Transplantation 1997;64: 716-720.
80. Vilchez RA, Fung J, Kusne S. Cryptococcosis in organ transplant recipients: an overview. Am J Transplant 2002; 2:575-580.
81. Vilchez R, Shapiro R, McCurry K, Kormos R, Abu-Elmagd K, Fung J, et al. Longitudinal study of cryptococcosis in adult solid-organ transplant recipients. Transpl Int 2003 May;16:336-340. Epub 2003 Mar 4.
82. Jabbour N, Reyes J, Kusne S, Martin M, Fung J Cryptococcal meningitis after liver transplantation. Transplantation 1996;61:146-149.
83. Saag MS, Graybill RJ, Larsen RA, Pappas PG, Perfect JR, Powderly WG, et al, Infectious Diseases Society of America: Practice guidelines for the management of cryptococcal disease. Clin Infect Dis 2000;30:710-718. Epub 2000 Apr 20.
84. Blair JE, Logan JL. Coccidioidomycosis in solid organ transplantation. Clin Infect Dis 2001;33:1536-1544. Epub 2001 Oct 4.